Kılınç, Faruk Dicle Üniversitesi - Tıp Fakültesi - Endokrinoloji Bilim Dalı, Türkiye , Alpağat, Gülistan Diyarbakır Eğitim ve Araştırma Hastanesi - Hastalıkları Kliniği, Türkiye , Demircan, Fatih Elazığ Özel Çağrı Tıp Merkezi - Hastalıkları Kliniği, Türkiye , Pekkolay, Zafer Dicle Üniversitesi - Tıp Fakültesi - Endokrinoloji Bilim Dalı, Türkiye , Gözel, Nevzat Fırat Üniversitesi - Tıp Fakültesi - Hastalıkları Kliniği, Türkiye , Tuzcu, Alpaslan Kemal Dicle Üniversitesi - Tıp Fakültesi - Endokrinoloji Bilim Dalı, Türkiye

Clinical and laboratory characteristics of exenatide-given patients in endocrinology clinic of a university hospital

26956

Objective: Exenatide has high affinity on binding GLP - 1 receptors. Endogenous GLP - 1 effects glucose-dependent insulin secretion, delayed gastric emptying, suppression of glucagon, inhibition of appetite, and shows effects of enhancing β - cell mass. It is usually use in the treatment of type 2 obese diabetic patients, whose treatment not be obtained with metformin and sulfonylurea or both. It was added to insulin therapy, because it provides better glycemic control and weight loss in cases which have high level of blood glucose with oral antidiabetic. In our study we planned to share the patients treated with exenatide in our clinic for a period of at least 4 months and discuss their biochemical and clinical parameters. Methods: In this study we evaluated 26 patients (2 males, 24 females) who admitted our clinic between July 2011 and December 2013 and who followed up at least 4 months (mean: 7.3) All of the patients were using metformin in combination with oral antidiabetic drug therapy, while 6 patients were receiving insulin therapy in addition to metformin. Results: After treatment, HemoglobineA1c decrease were found 0.98 % for women and 1.4% for men and of weight loss were found 0.64% for women and 0.57% for men, measurements of body mass index were decreased 0.61% for females and 0.56% for men. Conclusion: We determined that; addition of exenatide treatment to Insulin, metformin or oral antidiabetic therapy combination in obese patients leads to weight loss and decrease Hemoglobin A1c levels.

128

Exenatide , GLP , 1 , Diabetes mellitus

Dicle Medical Journal

132